Analytical comparability study of anti-CD20 monoclonal antibodies rituximab and obinutuzumab using a stability-indicating orthogonal testing protocol: Effect of structural optimization and glycoengineering
Moenes, Eman M; Al-Ghobashy, Medhat A; Nebsen, Marianne; Miriam Farid Ayad Ayad; Trabik, Yossra;
Abstract
Glycoengineering and biosimilarity are the key factors for growing, promising and progressive approaches in monoclonal antibodies development. In this study, the physicochemical stability of anti-CD20 rituximab (RTX); originator and biosimilar was compared to its glycoengineered humanized version; obinutuzumab (OBZ). An orthogonal stability-indicating protocol using a set of validated bioanalytical techniques; size exclusion high performance liquid chromatography (SE-HPLC), reversed phase liquid chromatography (RP-HPLC), quantitative gel electrophoresis by TapeStation, receptor binding assay and dynamic light scattering (DLS) was used to investigate the effect of different stress factors on the pattern and kinetics of degradation. SE-HPLC results supported with spectral purity showed similar degradation extent with a different pattern of degradation between RTX and OBZ. A lower tendency to form degraded fragments and a relatively higher favorability for degradation through aggregate formation has been revealed in case of OBZ. Results were in agreement with those of DLS and receptor binding assay which showed specificity to the intact antibodies in the presence of their degradation products. Furthermore, results were additionally confirmed through denaturing quantitative gel electrophoresis which suggested reducible covalent bonds as the mechanism for aggregates formation. RP-HPLC results showed two oxidized forms via excessive oxidation of RTX and OBZ with nearly the same degradation percent. Comparability data of RTX and OBZ using the applied methodologies showed that although glycoengineering; carried out to enhance the therapeutic and biological activity of OBZ altered the pattern of degradation but did not significantly affect the overall stability. Results showed also consistent stability profile between the biosimilar and its originator RTX products.
Other data
Title | Analytical comparability study of anti-CD20 monoclonal antibodies rituximab and obinutuzumab using a stability-indicating orthogonal testing protocol: Effect of structural optimization and glycoengineering | Authors | Moenes, Eman M; Al-Ghobashy, Medhat A; Nebsen, Marianne; Miriam Farid Ayad Ayad ; Trabik, Yossra | Keywords | Biosimilarity;Stability;Rituximab;Obinutuzumab;Glycoengineering | Issue Date | 30-Nov-2020 | Publisher | ELSEVIER | Journal | Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences | Volume | 1159 | Start page | 122359 | ISSN | 1570-0232 | DOI | 10.1016/j.jchromb.2020.122359 | PubMed ID | 32920338 | Scopus ID | 2-s2.0-85090407152 | Web of science ID | WOS:000589228200002 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.